Table 4 Relationship between the periods of TI prophylaxis and post-treatment hepatotoxicity by past history of hepatotoxicity.

From: Evaluate the value of prolonging the duration of tiopronin for injection administration in preventing hepatotoxicity

 

Crude model

Model 1

Model 2

Past history of hepatotoxicity (−) P-value/OR (95% CI)

 TI prophylaxis for ≥ 5 days

0.451

0.436

0.406

 TI prophylaxis for 1 day

0.282/2.031 (0.558–7.388)

0.098/3.744 (0.783–17.892)

0.087/3.931 (0.821–18.811)

 TI prophylaxis for 2 days

0.518/0.717 (0.261–1.968)

0.593/1.482 (0.350–6.267)

0.562/1.530 (0.363–6.442)

 TI prophylaxis for 3 days

0.458/0.688 (0.256–1.847)

0.766/1.214 (0.339–4.350)

0.749/1.231 (0,344–4.404)

 TI prophylaxis for 4 days

0.970/1.020 (0.358–2.905)

0.528/1.455 (0.453–4.673)

0.513/1.476 (0.460–4.732)

Past history of hepatotoxicity (+) P-value/OR (95% CI)

 TI prophylaxis for ≥ 5 days

0.720

0.487

0.516

 TI prophylaxis for 1 day

0.551/1.650 (0.319–8.542)

0.281/2.809 (0.429–18.392)

0.287/2.790 (0.422–18.428)

 TI prophylaxis for 2 days

0.338/1.768 (0.552–5.665)

0.136/3.250 (0.689–15.324)

0.163/3.058 (0.636–14.705)

 TI prophylaxis for 3 days

0.695/1.215 (0.459–3.214)

0.298/1.949 (0.555–6.846)

0.321/1.898 (0.535–6.732)

 TI prophylaxis for 4 days

0.786/0.864 (0.301–2.483)

0.845/1.122 (0.356–3.531)

0.886/1.088 (0.343–3.456)

  1. Model 1: adjusted for duration of chemotherapy drugs; Model 2: adjusted for duration of chemotherapy drugs and combinations of chemotherapeutic drugs. (+), positive ; (−), negative.